Newborns can't see clearly at birth. In fact, vision is about 20/400, making the first days of sight very blurry, like a camera out of focus. But within a week, a baby can focus on objects about 8 to 12 inches from his face.
(Wellâ¦sort of ânew.â) Tresiba is a long-acting insulin (like Lantus or Levemir) made by NovoNordisk. Itâs been available in Europe for several years now and is still awaiting FDA approval in the USA. (UPDATE: Tresiba is now approved by the FDA for use in the USA!)
Degludec is a much improved insulin to Levemir, which was much improved to NPH but Lantus is one of the greatest diabetes products of all time. It gave patients true innovation when launched, and Sanofi has over 75% of share of the long-acting basal market today. That market should grow when degludec is introduced..